GLP-1 receptor agonists have been shown to reduce systemic inflammation through several mechanisms: Reducing oxidative stress: GLP-1s can reduce oxidative stress, a key contributor to inflammation
This personalized approach is crucial, as it ensures that patients can reap the full benefits of retatrutide while maintaining their quality of life throughout treatment
You may experience a gap between how you see yourself and how your body looks, grief or confusion around identity, or even disappointment if the changes don't meet your expectations
Therefore, these equations cannot be used in patients with exogenous insulin use ( Despite important knowledge gaps in our understanding of IR in T1D, targeting IR in overweight/obese patients with T1D may decrease the risk of diabetes complications, contribute to weight loss, and improve glycemic control
Also, unlike therapies that are used to treat blood pressure or cholesterol, the perception that these are not chronic disease therapies may also be contributing
Final FDA-approved dosing (if approved) may differ
